Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI.

The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) live life to ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

He noted the significant early impact on CIDP and progress in clinical milestones, including advancing empasiprubart and efgartigimod into Phase III programs. Van Hauwermeiren announced that 2025 ...

and those with obvious underlying secondary CIDP etiologies including diabetes, autoantibodies, or an IgM monoclonal gammopathy. Patients with hypertension, other medical disorders preventing ...

One type, the immune-mediated demyelinating neuropathies, includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profileof VYVGART and VYVGART HytrulogMG patients on VYVGART ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

In a 2022 review of CIDP diagnosis, Allen and co-author Richard Lewis, MD, of Cedars-Sinai Medical Center in Los Angeles, ...